# Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 <scp>ESSENCE</scp> Trial

*PRI Rank #19 · Topics and Trends in Most Cited Liver Disease Diagnosis and Treatment Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/liver-disease-diagnosis-and-treatment/2026/rank-19*

| Field | Value |
| --- | --- |
| Rank | #19 |
| 18m citations | 114 |
| Journal | Alimentary Pharmacology & Therapeutics |
| Year | 2024 |
| DOI | 10.1111/apt.18331 |
| Corresponding authors | Philip N. Newsome |
| Institution | King's College London, United Kingdom |

**Ranking page:** [Topics and Trends in Most Cited Liver Disease Diagnosis and Treatment Papers, Class of 2026](https://pri.pepkio.com/top-papers/liver-disease-diagnosis-and-treatment/2026)

**Paper link:** [10.1111/apt.18331](https://doi.org/10.1111/apt.18331)

## Topics

Semaglutide · GLP-1 receptor agonists · Steatohepatitis · Steatohepatitis · ESSENCE trial · Fibrosis stage F2 · Fibrosis stage F3 · liver histology · Steatohepatitis resolution · Liver fibrosis improvement · type 2 diabetes · Metabolic dysfunction-associated steatotic liver disease · Metabolic dysfunction-associated steatotic liver disease · MASLD cardiometabolic criteria · Non-invasive diagnostic methods · Subcutaneous administration · phase 3 trial · Biopsy-confirmed steatohepatitis

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Liver Disease Diagnosis and Treatment Papers, Class of 2026. https://pri.pepkio.com/top-papers/liver-disease-diagnosis-and-treatment/2026. Accessed 2026-07-24.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```